zurück
Home |
Harnblasen - Karzinom: Studien |
| SWOG S1011 |
As compared with standard lymphadenectomy, extended lymphadenectomy did not
result in improved disease-free or overall survival among patients with muscle-invasive
bladder cancer undergoing radical cystectomy and was associated with higher peri-
operative morbidity and mortality (3). |
| NIAGARA |
Perioperative durvalumab plus neoadjuvant chemotherapy led to significant im-
provements in event-free survival and overall survival as compared with neoadju-
vant chemotherapy alone (4). |
| JAVELIN |
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma(2) |
| IMvigor-210 |
Atezolizumab (PD-L1-AK) |
| KEYNOTE-045 |
Pembrolizumab as Second-Line Therapy for Advanced
Urothelial Carcinoma |
| BA06-30894 |
Eine präoperative CMV-Chemotherapie erhöht die
10a-Überlebensrate radikal operierter oder bestrahlter muskelinvasiver
Blasenkarzinome signifikant! |
| CheckMate 274 |
AUO AB58/17Nivolumab versus Placebo bei invasivem Hoch-Risiko-Urothelkarzinom. |
| NCIC - Trial |
Improved local control of invasive bladder cancer by concurrent
cisplatin and preoperative or definitive radiation. |
| JCOG 0209 |
Randomised phase III study of neoadjuvant chemotherapy with
methotrexate, doxorubicin, vinblastine and cisplatin followed by radical
cystectomy compared with radical cystectomy alone for muscle-invasive bladder
cancer: Japan Clinical Oncology Group Study JCOG0209. |
| BC2001 |
Radiochemotherapie ist der alleinigen Strahlentherapie
überlegen. |
| BCON |
Addition of carbogen and nicotinamide (hypoxia-modifying
agents) to radiotherapy improves the survival |
| JASINT |
Die Kombination von Gemcitabin mit Vinflunin hatte bei
fortgeschrittenen oder metastasierten Urothelkarzinomen ähnliche
Tumoransprechraten, aber eine geringere Haematotoxizität als Carboplatin -
Vinfunin. |
| Thuroc |
Beobachtungsstudie der Mitomycin C - Instillation von NMIBC, pT1 oder pT1 oder CIS. Leiter Doehn, Lübeck. Rekrutiert. |
Teil von |
Harnblasen - Karzinom |
urologische Tumoren |
Onkologie |
| Quellen |
1.) J. Bellmunt, et al. for the KEYNOTE-045 Investigators:
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
N Engl J Med 2017;376:1015-26.
DOI: 10.1056/NEJMoa1613683
2.) Powles T, et al.:
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥ Years of Follow-Up.
J Clin Oncol 2023;41:3486-3492
doi 10.1200/JCO.22.01792
3.) Lerner S P, et al. for the SWOG S1011 Trial Investigators:
Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer.
N Engl J Med 2024;391:1206-16.
DOI: 10.1056/NEJMoa2401497
4.) Powles T, et al. for the NIAGARA Investigators:
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.
N Engl J Med 2024;391:1773-86.
DOI: 10.1056/NEJMoa2408154
|
 |